Table 5.

Adverse events during conversion to IPX066 (all treated patients)

Variable	Conversion	Conversion
	from	from
	IR CD-LD	CLE
N	450	110
Summary statistics, n (%)
Any AE	206 (45.8)	34 (30.9)
Mild	160 (35.6)	26 (23.6)
Moderate	85 (18.9)	14 (12.7)
Severe	15 (3.3)	2 (1.8)
Any serious AE	14 (3.1)	2 (1.8)
Discontinuation due to AEs	23 (5.1)	1 (0.9)
Death	2 (0.4)	0
AEs by Preferred Term a , n (%)
Dyskinesia	25 (5.6)	1 (0.9)
Nausea	24 (5.3)	8 (7.3)
Headache	19 (4.2)	2 (1.8)
Dizziness	17 (3.8)	1 (0.9)
On and off phenomenon	14 (3.1)	0
Fall	12 (2.7)	3 (2.7)
Anxiety	11 (2.4)	1 (0.9)
Dry mouth	11 (2.4)	0
Insomnia	11 (2.4)	1 (0.9)
Constipation	9 (2.0)	1 (0.9)
Vomiting	7 (1.6)	3 (2.7)
Upper respiratory tract infection	5 (1.1)	3 (2.7)

^aAEs are those reported in ≥2.0% of patients who began conversion to IPX066 in either study, and are listed by Medical Dictionary for Regulatory Activities Version 12.1 Preferred Term. AE, adverse event; CD, carbidopa; CLE, immediate-release carbidopa-levodopa plus entacapone; IR, immediate-release; LD, levodopa.